Physician profile
Frank Farrell
NPI 1891770905
$2,573.37
in general payments reported to CMS, 2019-2025
14 companies · $669 in 2025
The $669 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2020: $49.54 · 2021: $345 · 2022: $346 · 2023: $590 · 2024: $305 · 2025: $669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,517 · Education: $46.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,517.07 |
| Education | $46.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,120.75 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $369.58 | 2019-2023 | Xifaxan |
| Pfizer INC. | $253.10 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $204.05 | 2019-2025 | Entyvio |
| Medtronic, INC. | $129.51 | 2022-2025 | Gi Genius |
| Janssen Biotech, INC. | $114.36 | 2019-2025 | Tremfya, Stelara, Remicade |
| Celltrion USA INC. | $88.54 | 2023-2025 | Yuflyma, Vegzelma |
| Braintree Laboratories, INC. | $76.14 | 2023-2025 | Suflave, Sutab |
| Intercept Pharmaceuticals, INC. | $66.70 | 2019-2024 | |
| Lilly USA, LLC | $58.20 | 2024 | Omvoh |
| Celgene Corporation | $30.96 | 2024 | Zeposia |
| Genzyme Corporation | $21.81 | 2023 | |
| Redhill Biopharma INC. | $20.98 | 2021 | |
| Qol Medical, LLC | $18.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Farrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.